Blueprint Medicines Corp
BPMCDelisted Jul 18, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597264
Blueprint Medicines Corp was delisted on Jul 18, 2025; its insiders filed their last Form 4 on Jul 21, 2025; 356 institutions reported holding it in 13F filings for Q2 2025, worth $8.65B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Blueprint Medicines Corp as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
BPMC is no longer listed, and 13F filings after Q2 2025 list far fewer holders. See Q2 2025
- Institutional holders
- 12
- −338 vs. Q2 2025
- Shares held
- 37.9K
- −66.4M (−99.9%) vs. Q2 2025
- Total value
- $2.58M
- −$8.51B (−100.0%) vs. Q2 2025
- New holders
- 1
- 3 more added
- Sold out
- 339
- 4 more reduced
6 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BPMC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 4 | $129 |
| Q1 2026 | 6 | $38.6K |
| Q4 2025 | 8 | $2.57M |
| Q3 2025 | 12 | $2.58M |
| Q2 2025 | 356 | $8.65B |
| Q1 2025 | 353 | $6.12B |
| Q4 2024 | 346 | $5.86B |
| Q3 2024 | 319 | $6.04B |
| Q2 2024 | 305 | $7.15B |
| Q1 2024 | 282 | $6.25B |
| Q4 2023 | 260 | $5.91B |
| Q3 2023 | 220 | $3.25B |
| Q2 2023 | 222 | $4.03B |
| Q1 2023 | 215 | $2.84B |
| Q4 2022 | 223 | $2.74B |
| Q3 2022 | 240 | $4.15B |
| Q2 2022 | 237 | $3.19B |
| Q1 2022 | 248 | $3.82B |
| Q4 2021 | 280 | $6.32B |
| Q3 2021 | 289 | $6.13B |
| Q2 2021 | 281 | $5.14B |
| Q1 2021 | 264 | $5.69B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Blueprint Medicines Corp; share changes are against Q2 2025.